Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $195.92.
A number of brokerages recently weighed in on ASND. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. JPMorgan Chase & Co. cut their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday. Jefferies Financial Group lifted their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. Finally, Wells Fargo & Company upped their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th.
Read Our Latest Stock Report on ASND
Ascendis Pharma A/S Stock Performance
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. On average, equities research analysts forecast that Ascendis Pharma A/S will post -7.2 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in ASND. Hennion & Walsh Asset Management Inc. increased its stake in shares of Ascendis Pharma A/S by 14.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 7,034 shares of the biotechnology company’s stock worth $1,063,000 after acquiring an additional 882 shares during the last quarter. Private Ocean LLC purchased a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth about $36,000. Matisse Capital lifted its holdings in shares of Ascendis Pharma A/S by 2.6% during the 1st quarter. Matisse Capital now owns 35,540 shares of the biotechnology company’s stock valued at $5,373,000 after buying an additional 905 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Ascendis Pharma A/S by 4,231.4% in the 1st quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock valued at $11,419,000 after buying an additional 73,796 shares in the last quarter. Finally, Tobam increased its holdings in Ascendis Pharma A/S by 41.1% in the first quarter. Tobam now owns 2,163 shares of the biotechnology company’s stock worth $327,000 after buying an additional 630 shares during the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Stories
- Five stocks we like better than Ascendis Pharma A/S
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Texas Roadhouse Stock Steering for New Highs This Year
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Most Volatile Stocks, What Investors Need to Know
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.